Integrated Technologies Ltd. v. Biochem Immunosystems, (U.S.) Inc.

2 F. Supp. 2d 97, 1998 U.S. Dist. LEXIS 5412, 1998 WL 181281
CourtDistrict Court, D. Massachusetts
DecidedMarch 30, 1998
DocketC.A. 97-10627-DPW
StatusPublished
Cited by16 cases

This text of 2 F. Supp. 2d 97 (Integrated Technologies Ltd. v. Biochem Immunosystems, (U.S.) Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Massachusetts primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Integrated Technologies Ltd. v. Biochem Immunosystems, (U.S.) Inc., 2 F. Supp. 2d 97, 1998 U.S. Dist. LEXIS 5412, 1998 WL 181281 (D. Mass. 1998).

Opinion

*99 ORDER

WOODLOCK, District Judge.

The within recommendation is adopted on an order of this court.

REPORT AND RECOMMENDATION REGARDING BIOCHEM IMMUNOSYS-TEMS (U.S.), INC.’S MOTION TO DISMISS (DOCKET NO. 4)

KAROL, United States Magistrate Judge.

I. BACKGROUND

This case is the latest saga in a long and exceptionally stormy business relationship. To understand plaintiffs claims and the pending motion to dismiss, some background is in order.

In April 1988, plaintiff, Integrated Technologies Limited (“ITL”) (then known as Wilj International Limited and referred to herein as “plaintiff’ or “ITL”), entered into an agreement (the “1988 Agreement”) with defendant, BioChem Immunosystems (U.S.), Inc. or its predecessors in interest (collectively referred to herein as “defendant” or “Bio-Chem”), for the design, development, manufacture, and sale by ITL to BioChem of a diagnostic immunoassay instrument known as the SR-1. The 1988 Agreement was modified in March 1990 by a First Amendatory Agreement. The First Amendatory Agreement is the subject of the present dispute. The parties subsequently entered into two other agreements: (1) a March 1991 agreement, which attempted to resolve some warranty disputes that had arisen between ITL and BioChem (the “1991 Warranty Settlement”), and (2) a Settlement Agreement and Release dated May 26,1993 (the “Settlement Agreement”). Under the 1991 Warranty Settlement, ITL agreed to give BioChem a warranty allowance on BioChem’s previous purchases of SR-ls. The allowance was in the amount of £779,964, less certain adjustments, including a reduction equal to the amount of certain royalty payments that Bio-Chem would otherwise have owed ITL under the First Amendatory Agreement but which ITL agreed to forego. Within eighteen months of their entering into the 1991 Warranty Settlement, the parties had another falling out, resulting in ITL’s commencement of suit against BioChem in November 1992 in this court, C.A. No. 92-12748-K, (“ITL F). The Settlement Agreement purported to settle ITL I and included, as one of its terms, the dismissal of that case, with prejudice. The stipulation of dismissal with prejudice was executed and filed on June 16, 1993.

Again, peace eluded the parties’ grasp, and, on April 11, 1995, ITL commenced a second lawsuit in this court against BioChem, C.A. No. 95-10745-DPW (“ITL IF). In ITL II, which is still pending, ITL claims breach by BioChem of the Settlement Agreement, including failure by BioChem to fulfill certain payment obligations under the 1988 Agreement which BioChem allegedly reaffirmed in the Settlement Agreement. BioChem in turn asserts in a counterclaim breach by ITL of the 1991 Warranty Settlement.

In January 1997, ITL filed a motion in ITL II seeking leave to amend its complaint to add a claim for breach by BioChem of the First Amendatory Agreement. Specifically, the motion sought to add the following paragraph to the complaint:

BioChem is also liable for breach of its obligation under the parties’ First Amen-datory Agreement to purchase from [ITL] 30% of its requirements of certain diagnostic instruments between March 1,1990 and December 31, 1993, and to pay [ITL] certain royalties.

As a reason for not asserting such claim earlier, ITL maintained at a hearing before Judge Woodlock on January 27, 1997, that although it was a signatory to the First Amendatory Agreement, it had misplaced it and was, therefore, unaware of its provisions until BioChem produced a copy in April 1996. 1 Judge Woodlock denied ITL’s motion, stating:

[The motion] is not allowed for purposes of adding an additional claim here, which will *100 only delay the resolution of this lawsuit and appears to result from inexcusable negligence on the part of your client, negligence that’s not brought to the attention of the Court until after there is a determination of the close of discovery here. 2

ITL commenced the present lawsuit {“ITL III”) against BioChem in March 1997 in direct response to this decision. The complaint in ITL III has two counts. Count I alleges a breach by BioChem of its obligation under the First Amendatory Agreement to make certain minimum purchases and to pay certain royalties. Count II is for an accounting “of BioChem’s requirements of Instruments from March 1, 1990 until December 31, 1993” and “for the spare parts and Instruments on which it is required to pay royalties to ITL.” Presently before the court is BioChem’s motion under Fed.R.Civ.P. 12(b)(6) to dismiss both counts for failure to state a claim on which relief can be granted. Based upon various exhibits that it attaches to its motion and which set forth background information concerning ITL II, BioChem argues that the January 27, 1997 Order would effectively be reversed and the policy underlying Fed.R.Civ.P. 15 would be undercut if ITL were permitted to proceed with its complaint in ITL III. It also asserts in its motion that the equitable remedy of an accounting is not available to ITL under Massachusetts law because the parties are not in a fiduciary relationship and the damage issue that ITL seeks to raise is not so complicated that it cannot be resolved in an action at law. ITL vigorously opposes both of BioChem’s arguments on the merits and disputes BioChem’s statement of Massachusetts law regarding the conditions under which the equitable remedy of an accounting is available. It does not, however, take issue with BioChem’s attempt to present its policy arguments in the context of a motion under Fed.R.Civ.P. 12(b)(6) or with BioChem’s reliance on exhibits that it attaches to its motion. Taking my cue from the parties, I, too, shall assume that Fed.R.Civ.P. 12(b)(6) is an appropriate procedural device for raising policy arguments about the importance of judicial consistency and the need to vindicate Fed.R.Civ.P. 15 and that, in deciding this motion, I may take into account pleadings fried and orders entered in ITL II. See Watterson v. Page, 987 F.2d 1, 3 (1st Cir.1993) (although court ordinarily may not, in deciding a motion to dismiss, consider matters outside the four corners of the complaint, there is a “narrow exception[ ] for documents the authenticity of which are not disputed by the parties; for official public records; for documents central to plaintiffs’ claim; or for documents sufficiently referred to in the complaint”). 3

II. ANALYSIS

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Harrison v. Forde
S.D. Alabama, 2025
Hicks v. Redd
D. Massachusetts, 2019
Hicks v. Redd
378 F. Supp. 3d 55 (District of Columbia, 2019)
Pace v. Town of Erving
D. Massachusetts, 2018
Pace v. Town of Erving
294 F. Supp. 3d 5 (District of Columbia, 2018)
Lish v. First Security Bank of Nv
Nevada Supreme Court, 2014
Silva v. CITY OF NEW BEDFORD, MASS.
677 F. Supp. 2d 367 (D. Massachusetts, 2009)
Kucharski v. TRIBECA LENDING CORP.
620 F. Supp. 2d 147 (D. Massachusetts, 2009)
Shahidi v. Michael
2005 Mass. App. Div. 152 (Mass. Dist. Ct., App. Div., 2005)
Chief Justice Cushing Highway Corp. v. Limbacher
145 F. Supp. 2d 108 (D. Massachusetts, 2001)

Cite This Page — Counsel Stack

Bluebook (online)
2 F. Supp. 2d 97, 1998 U.S. Dist. LEXIS 5412, 1998 WL 181281, Counsel Stack Legal Research, https://law.counselstack.com/opinion/integrated-technologies-ltd-v-biochem-immunosystems-us-inc-mad-1998.